Citations

Clear

1446 citation(s) found for "Howard, F".

Feasibility of Use of a Smart Speaker to Administer Snellen Visual Acuity Examinations in a Clinical Setting
Ismail, Haroon O., Moses, Akini R., Tadrus, Matthew, Jones, Leslie S. , Mohamed, Essa A. , Moses, Akini R.

Mayo Clinic

JAMA Network Open | August 19, 2020 | Volume: 3 | Issue: 8 | Pages: e2013908

10.1001/jamanetworkopen.2020.13908 | PMID 32822489 Get It

Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Werner, Christian K. , Nna, Uchechi J. , Sun, Hanshi, Wilder-Romans, Kari , Dresser, Joseph, Kothari, Ayesha U. , Zhou, Weihua , Yao, Yangyang , Rao, Arvind , Stallard, Stefanie, Bor, Tarik , Debinski, Waldemar, Hegedus, Alexander M. , Morgan, Meredith A. , Venneti, Sriram , Baskin-Bey, Edwina, Spratt, Daniel E. , Colman, Howard , Speers, Corey , Lawrence, Theodore S. , Wahl, Daniel , Bor, Tarik , Hegedus, Alexander M , Colman, Howard , Speers, Corey , Lawrence, Theodore S , Spratt, Daniel E , Kothari, Ayesha U , Werner, Christian K , Koschmann, Carl , Sarkaria, Jann N. , Chinnaiyan, Arul , Eisner, Joel Robert , Strowd, Roy E.

Mayo Clinic

Molecular Cancer Therapeutics | August 12, 2020 | Volume: 19 | Issue: 10 | Pages: 2163-2174

10.1158/1535-7163.mct-20-0095 | PMID 32796101 Get It

Abstract New approaches are needed to overcome intrinsic therapy resistance in glioblastoma (GBM). Because GBMs exhibit sexual dimorphism and are reported to express steroid hormone receptors, we reasoned that signaling through the androgen receptor (AR) could mediate therapy resistance in GBM, much as it does in AR-positive prostate and breast cancers. We found that nearly half of GBM cell lines, patient-derived xenografts (PDX), and human tumors expressed AR at the transcript and protein level—with expression levels overlapping those of primary prostate cancer. Analysis of gene expression datasets also revealed that AR expression is higher in GBM patient samples than normal brain tissue. Multiple clinical-grade antiandrogens slowed the growth of and radiosensitized AR-positive GBM cell lines and PDXs in vitro and in vivo. Antiandrogens blocked the ability of AR-positive GBM PDXs to engage adaptive transcriptional programs following radiation and slowed the repair of radiation-induced DNA damage. These results suggest that combining blood–brain barrier permeable antiandrogens with radiation may have promise for patients with AR-positive GBMs.
E-212 Pulserider in the treatment of wide-neck bifurcation aneurysms: interim results of the NAPA trial
Spiotta, Alejandro M , Ebersole, Koji , Lena, Jonathan , Starke, Robert M. , Puri, A, Yavagal, Dileep R. , Bohnstedt, Bradley N. , Rangel-Castilla, Leonardo , Cheema, Ali, Rodrigues, K de Macedo , Grossberg, Jonathan A , Leacy, Reade De , Rangel-Castilla, Leonardo , Cheema, A, Davies, Jason M. , Howard, Brian M , Kellner, Christopher Paul , Lanzino, Giuseppe , Tateshima, Satoshi

Mayo Clinic

Electronic Poster Abstracts | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: A144.2-A145

10.1136/neurintsurg-2020-snis.243 Get It

Reduction in Pulmonary Vein Stenosis and Collateral Damage With Pulsed Field Ablation Compared With Radiofrequency Ablation in a Canine Model
Howard, Brian, Haines, David E. , Packer, Douglas L. , Kirchhof, Nicole , Barka, Noah , Önal, Birce , Fraasch, Steve, Miklavčič, Damijan , Stewart, Mark T. , Packer, Douglas, Onal, Birce , Verma, Atul

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 27, 2020 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/circep.120.008337 | PMID 32877256 Get It

Background: Pulmonary vein (PV) stenosis is a highly morbid condition that can result after catheter ablation for PV isolation. We hypothesized that pulsed field ablation (PFA) would reduce PV stenosis risk and collateral injury compared with irrigated radiofrequency ablation (IRF). Methods: IRF and PFA deliveries were randomized in 8 dogs with 2 superior PVs ablated using one technology and 2 inferior PVs ablated using the other technology. IRF energy (25–30 W) or PFA was delivered (16 pulse trains) at each PV in a proximal and in a distal site. Contrast computed tomography scans were collected at 0, 2, 4, 8, and 12-week (termination) time points to monitor PV cross-sectional area at each PV ablation site. Results: Maximum average change in normalized cross-sectional area at 4-weeks was −46.1±45.1% post-IRF compared with −5.5±20.5% for PFA ( P ≤0.001). PFA-treated targets showed significantly fewer vessel restrictions compared with IRF ( P ≤0.023). Necropsy showed expansive PFA lesions without stenosis in the proximal PV sites, compared with more confined and often incomplete lesions after IRF. At the distal PV sites, only IRF ablations were grossly identified based on focal fibrosis. Mild chronic parenchymal hemorrhage was noted in 3 left superior PV lobes after IRF. Damage to vagus nerves as well as evidence of esophagus dilation occurred at sites associated with IRF. In contrast, no lung, vagal nerve, or esophageal injury was observed at PFA sites. Conclusions: PFA significantly reduced risk of PV stenosis compared with IRF postprocedure in a canine model. IRF also caused vagus nerve, esophageal, and lung injury while PFA did not.
Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia
Zhang, Xu , Minniti, Caterina P. , Campbell, Andrew , Rana, Sohail , Luchtman‐Jones, Lori , Sable, Craig , Dham, Niti , Ensing, Gregory J., Arteta, Manuel , Taylor, James G. , Hsu, Lewis L. , Gordeuk, Victor R. , Kershaw, Kiarri N. , Darbari, Deepika S. , Nekhai, Sergei

Mayo Clinic

Blood Advances | July 24, 2020 | Volume: 4 | Issue: 14 | Pages: 3311-3314

10.1182/bloodadvances.2020002077 | PMID 32706890 Get It

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
Ailawadhi, Sikander , Jagannath, Sundar , Narang, Mohit , Rifkin, Robert M. , Terebelo, Howard R. , Durie, Brian G.M. , Toomey, Kathleen, Gasparetto, Cristina, Omel, James, Mia, HE, Yue, Lihua, Flick, E. Dawn, Agarwal, Amit , Abonour, Rafat , Investigators, Connect MM Registry, Wagner, Lynne , Ailawadhi, Sikander , Jagannath, Sundar , Lee, Hans C. , Hardin, James W. , Gasparetto, Cristina , Wagner, Lynne I. , Investigators, Connect MM Registry

Mayo Clinic

Cancer | July 24, 2020 | Volume: 126 | Issue: 19 | Pages: 4332-4340

10.1002/cncr.33089 | PMID 32706404 Get It

BackgroundStudies have reported racial disparities in access to and use of multiple myeloma (MM) treatments between African American (AA) and White patients. Although AA patients demonstrate longer disease‐specific survival, this has not uniformly translated into improved survival over time. The association between race and treatment patterns and survival outcomes was analyzed using data from the Connect MM Registry.MethodsThe Connect MM Registry is a large US, multicenter, prospective observational cohort study of patients with newly diagnosed MM. Patients who received first‐line (1L) stem cell transplantation (SCT) or who did not receive SCT (non‐SCT or non–stem cell transplantation [NSCT]) were grouped by raceEffects of race and transplantation status on the use of triplet treatment were estimated using logistic regression.ResultsTreatment patterns in 1L (types and duration of induction, posttransplantation maintenance) were similar between AA and White patients. SCT rates in 1L (32% vs 36%) and triplet treatment use (AA: 44% for NSCT patients and 72% for SCT patients; and White: 48% for NSCT patients and 72% for SCT patients) during first induction were similar. No significant effect of race or transplantation status on 1L triplet treatment use was observed. Race was not found to be associated with survival outcomes among patients who underwent NSCT; however, AA patients who received SCT had significantly longer overall survival compared with White patients who underwent SCT (not reached vs 88.2 months; hazard ratio, 0.56; 95% CI, 0.35‐0.89 [P = .0141]).ConclusionsAA and White patients were found to have similar treatment patterns in the Connect MM Registry, suggesting that both groups had equal access to health care. In this real‐world setting, AA patients received standard‐of‐care treatment, which might have contributed to better MM‐specific survival compared with White patients.
Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Wang, Guoqiao , Dincer, Aylin , Flores, Shaney , Keefe, Sarah , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Noble, James M. , Perrin, Richard J. , Visser, Pieter Jelle , Bateman, Randall J. , Gordon, Brian A. , (DIAN), Dominantly Inherited Alzheimer Network, Amtashar, Fatima, Bodge, Courtney, Brandon, Susan E. , Buck, Jill , Buckles, Virginia, Chea, Sochenda, Chrem, Patricio, Chui, Helena C., Cinco, Jake, Jack, Clifford, D’Mello, Mirelle , Donahue, Tamara, Douglas, Jane, Edigo, Noelia, Erekin-Taner, Nilufer, Fagan, Anne M. , Farlow, Marty, Farrar, Angela, Feldman, Howard , Flynn, Gigi, Franklin, Erin , Gant, Cortaiga, Gardener, Samantha L. , Gray, Julia, Gurney, Jenny , Hassenstab, Jason, Hirohara, Mie, Hornbeck, Russ C. , DiBari, Siri Houeland, Ikonomović, Snežana, Jerome, Gina, Klunk, William E. , Kuder-Buletta, Elke, Marcus, Daniel S. , Mason, Neal Scott, Maue-Dreyfus, Denise, Montoya, Lucy, Nagamatsu, Akem, Neimeyer, Katie, Norton, Joanne, Raichle, Marc, Ringman, John M. , Roh, Jee Hoon , Shiroto, Tomoyo, Sigurdson, Wendy, Sparks, Paige, Swisher, Laura, Taddei, Kevin , Wang, Peter, Weiner, Mike, Wolfsberger, Mary, Xiong, Chengjie, Tijms, Betty M , Gordon, Brian A , Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Cash, David M , Feldman, Howard H , Berman, Sarah , Ghetti, Bernardino , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Xiong, Chengjie , Scheltens, Philip , Benzinger, Tammie L.S. , Tijms, Betty M. , (DIAN), Dominantly Inherited Alzheimer Network, Allegri, Ricardo , Brandon, Susan, Brooks, William S. , Buck, Jill, Chui, Helena C. , Fujii, Hisako , Goate, Alison , Goldman, Jill , Hassenstab, Jason, Holtzman, David M. , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Kawarabayashi, Takeshi , Koeppe, Robert A. , Martins, Ralph N. , Shimada, Hiroyuki , Shoji, Mikio , Sohrabi, Hamid R. , Suzuki, Kazushi , Wang, Jen Chin C. , Xiong, Chengjie, Xu, Xiong, Noble, James M

Mayo Clinic

Brain Communications | July 15, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa102 | PMID 32954344 Get It

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort
Gentry, Melanie T. , Syrjanen, Jeremy A. , Calvert, Kendrick J., Hughes, Samantha R., Brushaber, Danielle , Kremers, Walter K. , Bove, Jessica, Brannelly, Patrick , Coppola, Giovanni , Dheel, Christina, Dickinson, Susan, Faber, Kelley, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Deb, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Haley, Dana , Heuer, Hilary W. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kornak, John , Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Manoochehri, Masood , McGinnis, Scott, Miller, Bruce L. , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Sengdy, Pheth, Shaw, Leslie M. , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , Calvert, Kendrick, Hughes, Samantha, Irwin, David J , Hsiung, Gink-Yuek , Miller, Bruce L , Kantarci, Kejal , Gentry, Melanie T , Kremers, Walter K , Lapid, Maria I. , Dickerson, Bradley, Fong, Jamie , Foroud, Tatiana , Gearhart, Deb, Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Knopman, David S. , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | July 13, 2020 | Volume: 16 | Issue: 8 | Pages: 1115-1124

10.1002/alz.12095 | PMID 32656921 Get It

AbstractObjectiveThe Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects evaluates familial frontotemporal lobar degeneration (FTLD) kindreds with MAPT, GRN, or C9orf72 mutations. Objectives were to examine whether health‐related quality of life (HRQoL) correlates with clinical symptoms and caregiver burden, and whether self‐rated and informant‐rated HRQoL would correlate with each other.MethodsIndividuals were classified using the Clinical Dementia Rating (CDR®) Scale plus National Alzheimer's Coordinating Center (NACC) FTLD. HRQoL was measured with DEMQOL and DEMQOL‐proxy; caregiver burden with the Zarit Burden Interview (ZBI). For analysis, Pearson correlations and weighted kappa statistics were calculated.ResultsThe cohort of 312 individuals included symptomatic and asymptomatic individuals. CDR® plus NACC FTLD was negatively correlated with DEMQOL (r = −0.20, P = .001), as were ZBI and DEMQOL (r = −0.22, P = .0009). There was fair agreement between subject and informant DEMQOL (κ = 0.36, P <.0001).ConclusionLower HRQoL was associated with higher cognitive/behavior impairment and higher caregiver burden. These findings demonstrate the negative impact of FTLD on individuals and caregivers.
Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values &lt; 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.